Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.

Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O

Diabetic medicine : a journal of the British Diabetic Association1 Aug 2005Cited by 99 (Europe PMC)

PMID16026367DOI10.1111/j.1464-5491.2005.01567.xPepBankPUB-16026367

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, weight change after 12 weeks ranged from -0.05 to -1.9% across the six treatment groups, which included the metformin group.
In plain wordsIn adults with type 2 diabetes, weight change after 12 weeks was small across all six groups, including the metformin group.
Peptide
Liraglutide
Outcome
Direction not reportedWeight change
Study
n = 210
Comparator
Metformin
Outcome group
Body weight · Metabolic and weight
Studied dose
0.045-0.75 mg once daily · 12 weeksAs given in this study (human).
Source sentences
Summary
After 12-week treatment, a weight change of -0.05 to -1.9% was observed for the six treatment groups.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, double-blind, parallel-group, double-dummy study explored the dose-response relationship of liraglutide effects on bodyweight and glycaemic control in subjects with Type 2 diabetes.
Summary · context
After a 4-week metformin run-in period, 210 subjects (27-73 years, 60% female) were randomised to receive liraglutide (0.045-0.75 mg) once daily or continued on metformin 1000 mg b.d. for 12 weeks.
Report a problemFND-1602636701
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, HbA1c rose by 1.28% from baseline after 12 weeks of liraglutide 0.045 mg.
In plain wordsIn adults with type 2 diabetes, HbA1c rose with the lowest liraglutide dose of 0.045 mg.
Peptide
Liraglutide
Outcome
IncreaseHbA1c change from baseline, 0.045 mg
Study
n: not reported in source
Comparator
Metformin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.045 mg once daily · 12 weeksAs given in this study (human).
Measurements
HbA1c change
1.28%
liraglutide 0.045 mg
Source sentences
Summary
Mean HbA(1c) changes from baseline for 0.045, 0.225, 0.45, 0.6, 0.75 mg liraglutide and metformin were +1.28%, +0.86%, +0.22%, +0.16%, +0.30% and +0.09%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, double-blind, parallel-group, double-dummy study explored the dose-response relationship of liraglutide effects on bodyweight and glycaemic control in subjects with Type 2 diabetes.
Summary · context
After a 4-week metformin run-in period, 210 subjects (27-73 years, 60% female) were randomised to receive liraglutide (0.045-0.75 mg) once daily or continued on metformin 1000 mg b.d. for 12 weeks.
Report a problemFND-1602636702
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, HbA1c rose by 0.86% from baseline after 12 weeks of liraglutide 0.225 mg.
In plain wordsIn adults with type 2 diabetes, HbA1c rose with liraglutide 0.225 mg.
Peptide
Liraglutide
Outcome
IncreaseHbA1c change from baseline, 0.225 mg
Study
n: not reported in source
Comparator
Metformin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.225 mg once daily · 12 weeksAs given in this study (human).
Measurements
HbA1c change
0.86%
liraglutide 0.225 mg
Source sentences
Summary
Mean HbA(1c) changes from baseline for 0.045, 0.225, 0.45, 0.6, 0.75 mg liraglutide and metformin were +1.28%, +0.86%, +0.22%, +0.16%, +0.30% and +0.09%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, double-blind, parallel-group, double-dummy study explored the dose-response relationship of liraglutide effects on bodyweight and glycaemic control in subjects with Type 2 diabetes.
Summary · context
After a 4-week metformin run-in period, 210 subjects (27-73 years, 60% female) were randomised to receive liraglutide (0.045-0.75 mg) once daily or continued on metformin 1000 mg b.d. for 12 weeks.
Report a problemFND-1602636703
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, HbA1c rose by 0.22% from baseline after 12 weeks of liraglutide 0.45 mg.
In plain wordsIn adults with type 2 diabetes, HbA1c rose slightly with liraglutide 0.45 mg.
Peptide
Liraglutide
Outcome
IncreaseHbA1c change from baseline, 0.45 mg
Study
n: not reported in source
Comparator
Metformin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.45 mg once daily · 12 weeksAs given in this study (human).
Measurements
HbA1c change
0.22%
liraglutide 0.45 mg
Source sentences
Summary
Mean HbA(1c) changes from baseline for 0.045, 0.225, 0.45, 0.6, 0.75 mg liraglutide and metformin were +1.28%, +0.86%, +0.22%, +0.16%, +0.30% and +0.09%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, double-blind, parallel-group, double-dummy study explored the dose-response relationship of liraglutide effects on bodyweight and glycaemic control in subjects with Type 2 diabetes.
Summary · context
After a 4-week metformin run-in period, 210 subjects (27-73 years, 60% female) were randomised to receive liraglutide (0.045-0.75 mg) once daily or continued on metformin 1000 mg b.d. for 12 weeks.
Report a problemFND-1602636704
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, HbA1c rose by 0.16% from baseline after 12 weeks of liraglutide 0.6 mg.
In plain wordsIn adults with type 2 diabetes, HbA1c rose slightly with liraglutide 0.6 mg.
Peptide
Liraglutide
Outcome
IncreaseHbA1c change from baseline, 0.6 mg
Study
n: not reported in source
Comparator
Metformin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg once daily · 12 weeksAs given in this study (human).
Measurements
HbA1c change
0.16%
liraglutide 0.6 mg
Source sentences
Summary
Mean HbA(1c) changes from baseline for 0.045, 0.225, 0.45, 0.6, 0.75 mg liraglutide and metformin were +1.28%, +0.86%, +0.22%, +0.16%, +0.30% and +0.09%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, double-blind, parallel-group, double-dummy study explored the dose-response relationship of liraglutide effects on bodyweight and glycaemic control in subjects with Type 2 diabetes.
Summary · context
After a 4-week metformin run-in period, 210 subjects (27-73 years, 60% female) were randomised to receive liraglutide (0.045-0.75 mg) once daily or continued on metformin 1000 mg b.d. for 12 weeks.
Report a problemFND-1602636705
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, HbA1c rose by 0.30% from baseline after 12 weeks of liraglutide 0.75 mg.
In plain wordsIn adults with type 2 diabetes, HbA1c rose slightly with liraglutide 0.75 mg.
Peptide
Liraglutide
Outcome
IncreaseHbA1c change from baseline, 0.75 mg
Study
n: not reported in source
Comparator
Metformin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.75 mg once daily · 12 weeksAs given in this study (human).
Measurements
HbA1c change
0.3%
liraglutide 0.75 mg
Source sentences
Summary
Mean HbA(1c) changes from baseline for 0.045, 0.225, 0.45, 0.6, 0.75 mg liraglutide and metformin were +1.28%, +0.86%, +0.22%, +0.16%, +0.30% and +0.09%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, double-blind, parallel-group, double-dummy study explored the dose-response relationship of liraglutide effects on bodyweight and glycaemic control in subjects with Type 2 diabetes.
Summary · context
After a 4-week metformin run-in period, 210 subjects (27-73 years, 60% female) were randomised to receive liraglutide (0.045-0.75 mg) once daily or continued on metformin 1000 mg b.d. for 12 weeks.
Report a problemFND-1602636706
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, HbA1c did not differ significantly between metformin and liraglutide at 0.45, 0.6 and 0.75 mg.
In plain wordsIn adults with type 2 diabetes, liraglutide at the three highest doses did not change HbA1c differently from metformin.
Peptide
Liraglutide
Outcome
No significant changeHbA1c versus metformin at the three highest doses
Study
n: not reported in source
Comparator
Metformin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.45, 0.6 and 0.75 mg once daily · 12 weeksAs given in this study (human).
Source sentences
Summary
No significant differences in HbA(1c) were observed between liraglutide and metformin groups at the three highest liraglutide dose levels (0.45, 0.6 and 0.75 mg).
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, double-blind, parallel-group, double-dummy study explored the dose-response relationship of liraglutide effects on bodyweight and glycaemic control in subjects with Type 2 diabetes.
Summary · context
After a 4-week metformin run-in period, 210 subjects (27-73 years, 60% female) were randomised to receive liraglutide (0.045-0.75 mg) once daily or continued on metformin 1000 mg b.d. for 12 weeks.
Report a problemFND-1602636707
08HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide 0.045 and 0.225 mg were not sufficient to maintain the fasting plasma glucose values achieved by metformin.
In plain wordsIn adults with type 2 diabetes, the two lowest liraglutide doses did not hold fasting blood sugar as well as metformin.
Peptide
Liraglutide
Outcome
Direction not reportedFasting plasma glucose at the two lowest doses
Study
n: not reported in source
Comparator
Metformin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.045 and 0.225 mg once daily · 12 weeksAs given in this study (human).
Source sentences
Summary
The lowest two liraglutide doses (0.045 mg and 0.225 mg) were not sufficient to maintain the fasting plasma glucose values achieved by metformin.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, double-blind, parallel-group, double-dummy study explored the dose-response relationship of liraglutide effects on bodyweight and glycaemic control in subjects with Type 2 diabetes.
Summary · context
After a 4-week metformin run-in period, 210 subjects (27-73 years, 60% female) were randomised to receive liraglutide (0.045-0.75 mg) once daily or continued on metformin 1000 mg b.d. for 12 weeks.
Report a problemFND-1602636708
09HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, no major hypoglycaemic episodes were reported with liraglutide.
In plain wordsIn adults with type 2 diabetes, no major low blood sugar episodes were reported with liraglutide.
Peptide
Liraglutide
Outcome
No significant changeMajor hypoglycaemic episodes
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.045-0.75 mg once daily · 12 weeksAs given in this study (human).
Source sentences
Summary
No major hypoglycaemic episodes were reported.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, double-blind, parallel-group, double-dummy study explored the dose-response relationship of liraglutide effects on bodyweight and glycaemic control in subjects with Type 2 diabetes.
Summary · context
After a 4-week metformin run-in period, 210 subjects (27-73 years, 60% female) were randomised to receive liraglutide (0.045-0.75 mg) once daily or continued on metformin 1000 mg b.d. for 12 weeks.
Report a problemFND-1602636709
10HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes, nausea and/or vomiting was reported by 11 patients (6.3%) on liraglutide and three (8.8%) on metformin.
In plain wordsIn adults with type 2 diabetes, nausea or vomiting affected 6.3% of people on liraglutide and 8.8% on metformin.
Peptide
Liraglutide
Outcome
Not applicableNausea and/or vomiting
Study
n: not reported in source
Comparator
Metformin
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.045-0.75 mg once daily · 12 weeksAs given in this study (human).
Measurements
Patients with nausea and/or vomiting
6.3%
liraglutide
Source sentences
Summary
Episodes of nausea and/or vomiting were reported by 11 patients (6.3%) receiving liraglutide and three (8.8%) receiving metformin.
2 context sentences(design, population, supporting numbers)
Summary · context
This multicentre, double-blind, parallel-group, double-dummy study explored the dose-response relationship of liraglutide effects on bodyweight and glycaemic control in subjects with Type 2 diabetes.
Summary · context
After a 4-week metformin run-in period, 210 subjects (27-73 years, 60% female) were randomised to receive liraglutide (0.045-0.75 mg) once daily or continued on metformin 1000 mg b.d. for 12 weeks.
Report a problemFND-1602636710

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2NCT01511198

Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic Agent

Novo Nordisk A/Sn = 223Feb 2001 to Oct 2001

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 26 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.